BioVie closed at $1.29 on Nov 4, down 25.14%, 43.2% below its 52-week closing high. Volume of 850.7K shares was 1.01× its 20-day average (close to normal).
Split-adjusted performance: -10.1% over one month, -22.0% over six months, -24.3% over one year.
Short interest was 544.4K shares at the Oct 15 settlement, down 34.5% from the prior report (7.8% of float, 2.8 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| BIVIBioVie | $1.30 | −25.14% | −22.0% | — | — | — | $11.2M | |
| RKTORocket One | $0.4444 | −3.85% | — | — | — | — | $11.1M | Compare |
| LSTALisata Therapeutics | $1.09 | −0.46% | −66.7% | −100.0% | — | — | $11.7M | Compare |
| TVRDTvardi Therapeutics | $0.8848 | +5.98% | −75.8% | — | — | — | $11.8M | Compare |
| LPCNLipocine | $1.46 | −0.34% | −40.1% | −100.0% | — | — | $12.0M | Compare |
| CLRBCellectar Biosciences INC NEW | $1.30 | −1.15% | −63.3% | — | — | — | $12.2M | Compare |
| HINDVyome Holdings | $1.75 | −1.41% | −20.7% | — | −2543.3% | — | $12.2M | Compare |
| PHIOPhio Pharmaceuticals | $0.8850 | −1.99% | −23.0% | — | — | — | $10.3M | Compare |
| ASBPAspire-Lakewood Holdings | $7.20 | −0.96% | +29.0% | — | −2009.6% | — | $10.1M | Compare |
No recent articles focused on BioVie.
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
